Results for: C-THR81-2405 PDF Questions with A Guaranteed Success 2024 ⚒ Easily obtain free download of “ C-THR81-2405 ” by searching on ⏩ www.pdfvce.com ⏪ 🤛Exam C-THR81-2405 Format

The Year in (P)review – MS 2013 – Is the Injectable Era (almost) Over?

The year 2013 will likely see the launch of two new oral agents for the treatment of multiple sclerosis – teriflunomide (already available in the U.S. as Aubagio), and BG-12. They will join fingolimod (Gilenya), the first of the oral MS drugs (following the withdrawal of cladribine). Fingolimod is indicated as a first-line (in the U.S.) or second-line (in Canada) treatment for relapsing forms of MS (RRMS). Subscribe to read more It takes 30 secon…

Pilot study of GSK-3 drug tested in AD

…A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2012; epublished August 30, 2012). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

RIS: what are the risk factors for CIS/MS?

…There has been little information on the natural history of radiologically isolated syndrome (RIS) since it was first described in 2009 (Okuda et al. Neurology 2009;72:800-805). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Neuroprotection: This is your brain on tea

The latest claimant to the neuroprotection crown is green tea, which provides therapeutic levels of the antioxidant EGCG (epigallocatechin gallate). A number of animal studies have indicated that EGCG may be beneficial in a range of disorders, including arthritis, colitis, Sjogren’s syndrome, and type 1 diabetes (Kim et al. J Nutr 2008;138:2111-2116; Oz et al. J Nutr Biochem 2005;16:297-304; Hsu et al. Autoimmunity 2007;40:138-147; Fu et al. Br J…